Golden Dragon (OTCMKTS:CPMD – Get Free Report) and Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Analyst Ratings
This is a summary of current ratings for Golden Dragon and Ocular Therapeutix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Golden Dragon | 0 | 0 | 0 | 0 | 0.00 |
| Ocular Therapeutix | 1 | 1 | 12 | 0 | 2.79 |
Ocular Therapeutix has a consensus price target of $23.78, indicating a potential upside of 163.90%. Given Ocular Therapeutix’s stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Golden Dragon.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Golden Dragon | $1.36 million | 1.24 | -$11.13 million | ($0.01) | -0.25 |
| Ocular Therapeutix | $52.04 million | 37.91 | -$265.94 million | ($1.46) | -6.17 |
Golden Dragon has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Golden Dragon, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
59.2% of Ocular Therapeutix shares are owned by institutional investors. 1.3% of Golden Dragon shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Golden Dragon and Ocular Therapeutix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Golden Dragon | -654.02% | N/A | -118.00% |
| Ocular Therapeutix | -558.24% | -64.28% | -48.15% |
Risk & Volatility
Golden Dragon has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Summary
Ocular Therapeutix beats Golden Dragon on 9 of the 14 factors compared between the two stocks.
About Golden Dragon
CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Golden Dragon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Golden Dragon and related companies with MarketBeat.com's FREE daily email newsletter.
